ST Shuangcheng: Etelcalcitide injection is granted marketing authorization in Australia.

ST Shuangcheng announcement: The company recently received the marketing approval for the injection of Isibapeptide from the Australian Therapeutic Goods Administration. This drug is used for patients undergoing non-emergent percutaneous coronary intervention and coronary artery stent placement, as well as for the treatment of patients with unstable angina or non-Q-wave myocardial infarction. Isibapeptide injection has already obtained marketing approval from the FDA in the United States and is widely sold globally. This approval from Australia will help the company expand its overseas market and improve its performance. However, the company reminds investors that the export sales of drugs may be affected by factors such as market demand, policy environment, exchange rates, and market competition, leading to uncertainty.